ClinicalTrials.gg
Active, not recruitingNCT05372679REDUCEDUpdated Nov 20, 2026

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

An interventional study of Renal denervation in Uncontrolled Stage 2 Hypertension, sponsored by SoniVie Inc.. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,032 studies in Hypertension with a site in United States — 268 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
1,446th of 1,780
25 · median 100
Started
2022
with 94 others
No phase
1,072 of 2,032
168 open now
Primary completion
2027-12
later than 221 of 367 live
Registered
1,577th of 2,032
by date

Among the 2,032 studies in Hypertension with a site in United States, this one is the 1,446th largest by enrollment of the 1,780 interventional ones that give a count, is one of 95 that started in 2022, is one of 1,072 with no phase, reaches primary completion later than 221 of the 367 other live ones, and was the 1,577th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

268 of the 2,032 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

263 more — sign in →

All 268 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,032 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness of the TIVUS™ System when used for renal artery denervation. The study will assess the acute and chronic safety of the procedure as well as the reduction in 24-hour ambulatory mean systolic blood pressure from baseline to 3 months after the procedure.

Read the detailed description

Nearly half of adults in the United States (108 million, or 45%) have hypertension defined as a systolic blood pressure ≥ 130 mm Hg or a diastolic blood pressure ≥ 80 mm Hg or are taking medication for hypertension. Hypertension is associated with cardiovascular and renal pathologies and leads to death if not treated appropriately. The cardiovascular risk factor doubles with each 20/10 mm Hg elevation in BP values above 115/75 mm Hg.

The current first-line therapy for hypertension involves change in life-style (i.e., diet and exercise) and various medications. However, only about 1 in 4 treated adults (24%) with hypertension have their condition under control. Thus, they are at increased risk for the major side effects of chronically elevated blood pressure, myocardial infarction, stroke, renal disease and heart failure. High blood pressure was a primary or contributing cause of death for more than 494,873 people in the United States in 2018, and was estimated to affect around 1.13 billion people worldwide and resulted in approximately 10 million deaths worldwide, in 2015.

About half of adults (45%) with uncontrolled hypertension have a blood pressure of 140/90 mm Hg or higher, now defined as Stage 2 hypertension. This includes 37 million U.S. adults. About 30 million adults are recommended to take medication. Almost two out of three of this group (19 million) have a blood pressure of 140/90 mm Hg or higher. The other 17 million adults are taking medications but are unable to lower their blood pressure below 140/90 mm Hg and are thus at increased risk for the risks associated with uncontrolled high blood pressure9. High blood pressure costs the United States about $131 billion each year, averaged over 12 years from 2003 to 2014.

In the past decade, several devices were developed in order to target the autonomic nervous system and lower BP in patients with uncontrolled hypertension. These devices aim to provide additional treatment option for patients who do not respond to antihypertensive medication. These devices target other BP regulating mechanisms such as baroreflex activation, deep brain stimulation carotid body ablation, direct vagus nerve stimulation, cardiac neuromodulation, central iliac arteriovenous coupler as well as other devices are currently under research, however, there is no medical device that has been approved so far.

The Therapeutic Intra Vascular UltraSound (TIVUS™) System is designed for renal artery nerve ablation using transluminal ultrasound (US). The TIVUS™ System is a high intensity, non-focused, ultrasound catheter system, which enables remote, localized, controlled, and repeatable thermal modulation of nerves adjacent to arterial vessel wall for performing safe and effective therapeutic artery sympathetic denervation. The ultrasonic energy is transmitted from a catheter positioned within the artery lumen, while avoiding direct contact with the artery wall.

03

Conditions studied

  • Uncontrolled Stage 2 Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written to participate in the study obtained from the patient, according to local regulations, prior to initiation of any study mandated procedure.
  2. Male or female, ≥ 18 years of age and ≤ 80 years of age at the time of screening.
  3. Individual has office systolic blood pressure (SBP) ≥ 140 mm Hg but \< 180 mm Hg, and a diastolic blood pressure (DBP) ≥ 90 mm Hg but \< 110 mm Hg based on an average of 3 office seated blood pressure readings measured by a manual, automated or semi-automated validated BP monitor, on current medications. 4. Documented mean daytime ABPM systolic blood pressure (SBP) ≥ 135 mm Hg but \< 180 mm Hg, after a 4 week stabilization period.

5. Patient is either on at least one anti-hypertensive medication at maximal tolerated dose with a medically documented intolerance to one or more medications, or on three medications where one is a diuretic.

6. Patient is willing and expected to maintain their anti-hypertensive medication regimen for at least 3 months.

7. Patient is able and willing to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patient has been previously diagnosed with abnormal renal artery anatomy and/or renal anatomy such as single kidney, other renal development anomaly such as ectopic or horseshoe kidney, or polycystic kidney disease precluding renal denervation therapy as detailed in the angiographic exclusion criteria.
  2. Pregnant or breastfeeding women or women planning a pregnancy within 12 months of study enrollment.
  3. Patient has an estimated (eGFR) of \< 40mL/min/1.73m2 CKD-EPI as calculated using the CKD-EPI 2021 equation.
  4. Patients with uncontrolled rapid AF.
  5. Patient has had a previous renal denervation procedure.
  6. Patients with daytime ABPM mean systolic blood pressure (SBP) > 180 mm Hg.
  7. Patient has Type 1 diabetes or poorly controlled Type 2 diabetes ( > 9%).
  8. Patients with history of myocardial infarction, unstable angina pectoris, heart failure, cerebrovascular accident, or widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.
  9. Patient has a planned major surgery or cardiovascular intervention in the next 6 months.
  10. Patient who has undergone a major surgery or cardiovascular intervention in the previous 3 months.
  11. Patient has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.
  12. Patient is taking therapy for diseases featuring vasculitis.
  13. Patient on anticoagulant therapy that cannot be temporarily withheld for study procedure.
  14. to recommended denervation procedure medications or intravascular contrast that cannot be adequately controlled with pre-medication.
  15. Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints. For patient previously participating in a drug trial, allow a wash-off period of at least 5 half-lives of the drug.
  16. Patient with significant co-morbid condition(s) which, at the discretion of the PI, are deemed to prohibit study entry.
  17. Patient works the night shift.
  18. Patient has valvular stenosis with risk of cardiac event with significant and/or abrupt decline in systolic blood pressure.
  19. Untreated secondary cause of hypertension.
  20. Device therapy within the past five years for the treatment of hypertension.
  21. Prior renal stent or angioplasty.
  22. \<1 year.
  23. Patients with history of renal transplant or planned renal transplantation within the next year.
  24. History of one or more episodes of severe orthostatic hypotension within the past year.
  25. Patient has unstable cardiac or pulmonary disease (including pulmonary hypertension) requiring chronic oxygen support.
  26. Uncontrolled or inadequately treated bleeding diathesis.
  27. Evidence of active infection within 7 days of procedure

Angiographic Exclusion Criteria

The following characteristics identified either on the renal artery CT scan or on the Eligibility II Renal artery Angiogram will prevent the patient from being included:

  1. Main renal arteries \< 4 mm in lumen diameter or \< 20 mm in length; accessory renal arteries, if present, \< 4 mm in lumen diameter or \<10 mm in length.
  2. Aorto-renal angle that in the operator's opinion prevents a safe cannulation of the renal artery.
  3. Severe common femoral artery, common and/or external iliac artery, renal, iliac or aortic calcification or tortuosity that may compromise the safe performance and completion of the TIVUS™ procedure.
  4. Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, in the operator's opinion, would interfere with safe cannulation of the renal artery or meets local standards for surgical repair or interventional dilation (NOTE: vessel areas with calcification and fibromuscular dysplasia (FMD) should be avoided as intended treatment areas).
  5. Any renal artery stenosis > 30% by visual assessment.
  6. Any renal artery aneurysm (>50% of the main renal artery reference vessel diameter by visual estimate).
  7. Presence of fibromuscular dysplasia
  8. Significant renal artery atheroma, aneurysm, calcification in the target vessel identified on CT Angiogram
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Renal denervation

    Denervating the sympathetic nerves surrounding the renal vasculature using unfocused ultrasound

    Device: Renal denervation

Interventions

  • DeviceRenal denervation

    The TIVUS system will be used for renal denervation

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    acute treatment related adverse events including including all-cause mortality, acute kidney injury, significant embolic event, renal artery perforation or dissection requiring intervention, vascular complications, stroke, myocardial infarction, or transient ischemic attack, deterioration in renal function end-stage renal failure, hospital admission for hypertensive crisis not related to confirmed nonadherence with medications or the protocol, new renal artery stenosis of more than 70% and major access site complications or cardiovascular complications

    Time frame: from baseline to 1 month post procedure

  2. Incidence of Adverse Events

    chronic treatment related adverse events including including all-cause mortality, acute kidney injury, significant embolic event, renal artery perforation or dissection requiring intervention, vascular complications, stroke, myocardial infarction, or transient ischemic attack, deterioration in renal function end-stage renal failure, hospital admission for hypertensive crisis not related to confirmed nonadherence with medications or the protocol, new renal artery stenosis of more than 70% and major access site complications or cardiovascular complications

    Time frame: from baseline to 12 month post procedure

  3. Change in mean daytime ambulatory systolic BP

    Reduction in daytime ambulatory mean systolic blood pressure from baseline to 3 months after the procedure.

    Time frame: From baseline to 3 months post procedure

Secondary outcomes

  1. Change in mean 24-hr ambulatory systolic and diastolic bp

    Reduction of 24-hour ambulatory mean systolic and diastolic blood pressure from baseline

    Time frame: 3, 6, 12, 24, 36 months

  2. Change in mean 24-hr ambulatory diastolic bp

    Reduction of 24-hour ambulatory mean diastolic blood pressure from baseline

    Time frame: 3 months

  3. Change in mean daytime ambulatory systolic bp

    Reduction of daylight ambulatory mean systolic blood pressure from baseline

    Time frame: 6, 12, 24, 36 months

  4. Change in mean nighttime ambulatory systolic and diastolic bp

    Reduction of nighttime ambulatory mean systolic and diastolic blood pressure from baseline

    Time frame: 3, 6, 12, 24, 36 months

  5. Change in mean office systolic and diastolic BP

    Reduction of office mean systolic and diastolic blood pressure from baseline

    Time frame: 3, 6, 12, 24, 36 months

  6. Change in mean 24-hr ambulatory pulse

    Reduction in mean 24-hour ambulatory pulse pressure from baseline

    Time frame: 3, 6, 12, 24, 36 months

  7. Rate of patients achieving target 24-hr ambulatory mean systolic BP

    Number of patients achieving target 24-hour ambulatory mean systolic blood pressure (\<130 mm Hg)

    Time frame: 3, 6, 12, 24, 36 months

  8. Rate of patients achieving target office systolic BP

    Number of patients achieving target office systolic blood pressure (\<140 mm Hg)

    Time frame: 3, 6, 12, 24, 36 months

  9. Change in number of antihypertensive medications taken

    Reduction in the number of antihypertensive medications taken and/or the dose taken

    Time frame: 6, 12 months

  10. Percentage of patients who respond to treatment

    Percentage of patients who respond to the treatment, with response defined as a reduction of at least 10mm in mean 24-hour ambulatory systolic blood pressure

    Time frame: 3, 6, 12 months

  11. Incidence of hypertensive or hypotensive emergency episodes

    Incidence of hypertensive or hypotensive emergency episodes resulting in hospitalization

    Time frame: 3, 6, 12 months

  12. Change in renal function based on laboratory parameters

    Changes in renal function, based on laboratory parameters such as eGFR (CKD-EPI) and serum creatinine

    Time frame: 3, 6, 12 months

  13. Change in renal function based on artery stenosis

    Changes in renal function, based on artery stenosis (\>70%)

    Time frame: 6, 12 months

  14. Incidence of heart failure

    Episodes of heart failure events

    Time frame: 3, 6, 12 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

Of 95 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 61 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 13, 2022
StartActual
Nov 11, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05372679
Lead sponsor
SoniVie Inc.
Responsible party
Sponsor
First posted
May 13, 2022
Start date
Nov 11, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Ajay Kirtane, MD
principal investigator · Columbia University/NYPH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion